Eric Lefkofsky, founder and CEO of Tempus AI, explains the impact of acquiring Ambry, a genetic testing company, which ...

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report ...

Experts say Investors may be valuing AI companies too generously if health systems can’t justify the costs of these tools.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

In a regulatory filing on Friday, Tempus AI (TEM) disclosed that Chairman and CEO Eric Lefkofsky sold a series of shares beginning on January 22, totaling about $62M. On January 22, Lefkofsky sold a ...

And, according to Eric Lefkofsky, Founder and CEO of Tempus, the acquisition “complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability ...

and life sciences companies,” said Eric Lefkofsky, Founder and CEO of Tempus. “We are excited to welcome Ambry to the Tempus team as we work together to improve patient outcomes and transform ...

and life sciences companies,” said Eric Lefkofsky, founder and CEO of Tempus AI. “We are excited to welcome Ambry to the Tempus team as we work together to improve patient outcomes and ...